Edition:
United Kingdom

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

41.17USD
23 Aug 2019
Change (% chg)

$-1.52 (-3.56%)
Prev Close
$42.69
Open
$42.69
Day's High
$42.72
Day's Low
$41.00
Volume
1,836,484
Avg. Vol
1,868,063
52-wk High
$43.65
52-wk Low
$31.57

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $58,810.70
Shares Outstanding(Mil.): 1,390.65
Dividend: --
Yield (%): --

Financials

  BSX.N Industry Sector
P/E (TTM): 44.45 102.12 33.85
EPS (TTM): 0.95 -- --
ROI: -- 6.09 12.69
ROE: -- 8.40 17.13

Boston Scientific's narrow profit beat fails to excite investors

Boston Scientific Corp narrowly beat Wall Street estimates for quarterly profit on Wednesday, helped by higher sales of its surgical products used to treat urological and pelvic conditions.

24 Jul 2019

UPDATE 2-Boston Scientific's narrow profit beat fails to excite investors

July 24 Boston Scientific Corp narrowly beat Wall Street estimates for quarterly profit on Wednesday, helped by higher sales of its surgical products used to treat urological and pelvic conditions.

24 Jul 2019

Boston Scientific profit falls 72% on acquisition charges

July 24 U.S. medical device maker Boston Scientific Corp reported a 72.3% drop in second-quarter profit on Wednesday, hit by charges related to its acquisition of Britain's BTG Plc.

24 Jul 2019

Boston Scientific trims 2019 sales growth forecast on weak first quarter, shares fall

Boston Scientific Corp on Wednesday posted a rare first-quarter profit and revenue miss and lowered the top end of its 2019 sales growth forecast as the medical device maker faces regulatory scrutiny for some of its products.

24 Apr 2019

Boston Scientific sees $25 million hit to 2019 revenue from mesh withdrawal

Boston Scientific Corp on Wednesday said it expects a setback of about $25 million to its full-year revenue due to the U.S. Food and Drugs Administration's order to halt sales of its transvaginal surgical mesh products.

17 Apr 2019

Boston Scientific sees $25 mln hit to 2019 revenue from mesh withdrawal

April 17 Boston Scientific Corp on Wednesday said it expects a setback of about $25 million to its full-year revenue due to the U.S. Food and Drugs Administration's order to halt sales of its transvaginal surgical mesh products.

17 Apr 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates